Navigation Links
Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
Date:12/7/2010

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after receiving a median of five prior lines of therapy (corresponding to a median of 13 anti-myeloma agents) and whose disease was refractory to their last therapeutic regimen. In addition, patients enrolled in the study had progressive disease upon entering the trial.  The clinical benefit rate (CBR) (minimal response or greater) in the study population was 34.2 percent.  The median overall survival (OS) was 15.5 months. Overall survival for responding patients (greater than or equal to minimal response) has not yet been reached; however, based on current data is expected to exceed 19 months.

Seventy-seven percent of patients had grade 1/2 peripheral neuropathy (PN) upon entry into the study.  New or worsening of PN was uncommon and Grade 3 PN occurred in less than 1 percent of patients. There were no Grade 4 PN events. A subset analysis of patients with PN (n= 202) on study was also presented at ASH.  Efficacy responses in patients with baseline PN were comparable to those seen in the full study population with an ORR of 24 percent and CBR of 34 percent. Based on the full 003-A1 results, Onyx plans to submit a New Drug Application (NDA) filing as early as mid-2011 for potential accelerated approval in the U.S.

These data are being presented today at the 52nd American Society of Hematology Annual Meeting in Orlando by David Siegel, M.D., Ph.D., Division Chief for Myelo
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Your ... advances in modeling lithium-ion battery storage capacity. , ... from a theoretical model created at Lawrence ... that predicts how carbon components will perform ... storage emphasizes the urgent need for higher-performance batteries. ...
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... HARBIN, China, Feb. 24 /PRNewswire-Asia-FirstCall/ -- China ... or "the Company") (Nasdaq: CSKI ... over-the-counter,drugs in the People,s Republic of China ... Peng Lai Jin Chuang Pharmaceutical Company ("Jin,Chuang"), ...
... biotech company in Madison, Wisconsin is so concerned about ... that they have volunteered to give away free bottles ... the incoming administration who has forgotten to pay taxes ... government employees in positions of responsibility have many important ...
... -- Quarter Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch ... VPHM ) reported today its financial results for the fourth ... 30, 2008 include:Operational: , , , ... Lev Pharmaceuticals, Inc. (Lev) in October 2008; , ...
Cached Biology Technology:China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 3Mental Stimulus Package: Government Officials who Forgot to Pay Taxes Will Receive Free Memory-boosting Supplement 2Mental Stimulus Package: Government Officials who Forgot to Pay Taxes Will Receive Free Memory-boosting Supplement 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12
(Date:7/25/2014)... congenital central nervous system disease that is caused ... during the embryonic phase. Many patients have varying ... neurocognitive retardation. Such problems decrease the patients, functional ... Ankara Physical Medicine and Rehabilitation Education and Research ... with SB, using the Pediatric Evaluation of Disability ...
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire-iReach/ -- ... managing data from cardiac devices, has cut emergency room ... the UC San Diego (UCSD) Medical Center, according to ... Journal. The UCSD Emergency Departments are using the suite ... such as pacemakers or defibrillators. "Using Geneva,s ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... Georgian town of Reepham in Norfolk are taking part in ... Anglia (UEA). Like two million homes across the ... warmth and hot water, and the aim of the UEA ... a viable option. The renewable fuel being used is ...
... a striking similarity between heart disease and Duchenne muscular ... that a new class of experimental drugs for heart ... At first glance, heart failure and the muscle-wasting ... usually before the age of 6, destroying their muscle ...
... GAITHERSBURG, Md.The bacterium behind one of mankind,s deadliest scourges, ... Institute of Standards and Technology (NIST) and the Department ... answering the decades-old question of what controls the switching ... of life,s functions. In a Journal of ...
Cached Biology News:Trailblazing rural community shows green heating oil a viable option 2While focusing on heart disease, researchers discover new tactic against fatal muscular dystrophy 2Long-sought protein structure may help reveal how 'gene switch' works 2Long-sought protein structure may help reveal how 'gene switch' works 3
Mouse anti human pro-Relaxin-2...
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... polyclonal to ErbB 2 - BSA ... for all tested applications). ... conjugated to KLH, corresponding to C ... c-ErbB2 Entrez GeneID: ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Biology Products: